The drug discovery has gained pace in the last decade as the healthcare sector has developed rapidly with the aim to improve the life quality and expectancy of the people. Drug discovery is a capital intensive process and a lot of investment is being witnessed in the biologics drug discovery sector. People are looking for alternatives to find the cure of diseases with minimal side-effects, and biologic therapies have been successful in treating chronic inflammatory diseases. The biologic drugs helped the patients by reducing their dependence on healthcare and improving their physical functions to live independently.
Since the approval of Humulin, recombinant human insulin, in 1982, biologic drug discovery market has gained pace steadily to become a global market. The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is projected to grow over $22.7 billion by 2025. The biologic drug sector has introduced targeted therapies which have gained traction. Moreover, the adoption of patient centric personalized medicine has risen considerably which is driving the growth of the biologics drug market. The ongoing research and development in the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression, have encouraged the use of different living factories in the development of novel therapeutic biologic drugs.
The process of drug discovery involves different stages of discovery, viz. target identification, hit generation, lead identification, and lead optimization. The lead optimization stage has been the biggest contributor in the market in the year 2016. Another bifurcation of the biologics drug market can be on the basis of the manufacture, viz. in-house and outsourced. In 2016, the in-house market for biologics drug discovery was estimated to be $6.5 billion, however, the CAGR was highest for the outsourced manufacturing.
Among the different drug product types, monoclonal antibody and recombinant protein are the prominent ones in the market. The monoclonal antibody segment is expected to reach $10.7 billion by 2025. During 2017 and 2025, biologics are expected to contribute 50% to the sales of the top hundred products, which will result in an increased investment in the research and development in the biologics drug discovery market. The latest research and development activities being Roche’ Ocrelizumab and Sanofi’s Dupilumab in 2016, and Ocrevus (Ocrelizumab) and Dupixient (dupilumab) in 2017, which were among the top two launches this year, so far.
The industry is witnessing ground-breaking research like the development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy and bio-betters, which have opened a pool of opportunities for the growth of the biologics drug discovery market. BIS Healthcare has conducted an extensive market research on ‘Global Biologics Drug Discovery Market -Analysis and Forecast (2017-2025)‘. The market intelligence report aims to provide an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which include drivers, restraints, and opportunities prevailing in the industry.
For further queries, please write to us at [email protected] or call us at +1 650 228 0182.